サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1533751

血液がん治療薬の世界市場

Blood Cancer Therapeutics

出版日
ページ情報
英文 291 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
血液がん治療薬の世界市場
出版日: 2024年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 291 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

血液がん治療薬の世界市場は2030年までに606億米ドルに達する見込み

2023年に388億米ドルと推定される血液がん治療薬の世界市場は、2030年には606億米ドルに達し、分析期間2023-2030年のCAGRは6.6%で成長すると予測されます。本レポートで分析したセグメントの1つである慢性骨髄性白血病（CML）治療薬は、CAGR 6.6%を記録し、分析期間終了までに136億米ドルに達すると予測されます。急性リンパ性白血病（ALL）治療薬セグメントの成長率は、分析期間中CAGR 7.7%と推定されます。

米国市場は106億米ドル、中国はCAGR 10.5％で成長すると予測

米国の血液がん治療薬市場は2023年に106億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに131億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは10.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.8%と6.5%と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

主要動向と促進要因

血液がんは、白血病、リンパ腫、骨髄腫など、血液、骨髄、リンパ系に影響を及ぼす悪性腫瘍の幅広いカテゴリーを包含します。血液がんの治療法は、過去数十年の間に大きな進歩を遂げたが、これは主にこれらの疾患の遺伝的・分子的基盤に対する理解の深まりによるものです。治療法には、化学療法、標的療法、免疫療法、幹細胞移植などがあり、それぞれ血液がんの種類や病期に合わせて調整されています。例えば、チロシンキナーゼ阻害剤のような標的療法は、がん細胞の増殖経路を特異的に阻害することで、慢性骨髄性白血病の治療を一変させました。一方、CAR-T細胞療法のような免疫療法は、患者自身の免疫細胞を再プログラミングして悪性細胞を攻撃させることで、ある種の進行した血液がんの治療に目覚ましい成功を示しています。

最近の血液がん治療薬の動向では、治療決定の指針となる遺伝子プロファイリングとバイオマーカー検査に焦点を当てた個別化医療が重視されています。このアプローチは、個々の患者にとって最も効果的な治療レジメンを特定するのに役立つだけでなく、副作用のリスクも最小限に抑えることができます。さらに、二重特異性抗体やチェックポイント阻害剤のような新規薬剤の統合は、腫瘍内科医が利用できる治療手段を拡大し、耐性がんや再発がん患者に新たな希望をもたらしています。研究が進むにつれて、有効性を高め、がんの再発の可能性を減らすことを目的とした、マルチモーダル治療戦略におけるこれらの先進的治療法の併用がますます一般的になっています。

血液がん治療薬市場の成長は、世界の血液がんの罹患率の増加、人口の高齢化、ヘルスケア投資の増加など、いくつかの要因によってもたらされます。また、より効果的で毒性の少ない治療法の選択肢につながるため、医薬品開発やがんゲノム解析における技術の進歩も極めて重要です。さらに、新しい薬剤の組み合わせや配列を試験する臨床試験の拡大が、この分野における技術革新のペースを加速させています。がん研究に対する公的・民間部門の資金援助は、最新の治療法に対する認識とアクセスを高めるためのアドボカシー活動や患者教育活動とともに、重要な役割を果たしています。市場の拡大は、画期的な治療法の承認プロセスを合理化し、患者への提供を早める規制当局によってさらに支えられています。

調査対象企業の例（注目の42社）

  • AbbVie, Inc.
  • Amgen, Inc.
  • Arcellx
  • BeiGene
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics, Inc.
  • Kite Pharma, Inc.
  • Kura Oncology
  • Novartis International AG
  • Oncolyze Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • TScan Therapeutics;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26829

Global Blood Cancer Therapeutics Market to Reach US$60.6 Billion by 2030

The global market for Blood Cancer Therapeutics estimated at US$38.8 Billion in the year 2023, is expected to reach US$60.6 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2023-2030. Chronic Myeloid Leukemia (CML) Therapeutics, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$13.6 Billion by the end of the analysis period. Growth in the Acute Lymphocytic Leukemia (ALL) Therapeutics segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.6 Billion While China is Forecast to Grow at 10.5% CAGR

The Blood Cancer Therapeutics market in the U.S. is estimated at US$10.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$13.1 Billion by the year 2030 trailing a CAGR of 10.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Key Trends and Drivers

Blood cancer encompasses a broad category of malignancies that affect the blood, bone marrow, and lymphatic system, including leukemias, lymphomas, and myeloma. The therapeutic landscape for blood cancers has seen substantial advances over the past few decades, largely driven by a deeper understanding of the genetic and molecular bases of these diseases. Treatment modalities include chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation, each tailored to the specific type of blood cancer and its stage. For instance, targeted therapies such as tyrosine kinase inhibitors have transformed the treatment of chronic myeloid leukemia by specifically inhibiting cancer cell proliferation pathways. Meanwhile, immunotherapies like CAR-T cell therapy have shown remarkable success in treating certain types of advanced blood cancers by reprogramming the patient’s own immune cells to attack malignant cells.

Recent developments in blood cancer therapeutics have emphasized personalized medicine, focusing on genetic profiling and biomarker testing to guide treatment decisions. This approach not only helps in identifying the most effective treatment regimens for individual patients but also minimizes the risk of adverse effects. Furthermore, the integration of novel agents such as bispecific antibodies and checkpoint inhibitors is expanding the therapeutic arsenal available to oncologists, offering new hope to patients with resistant or relapsed cancers. As research continues, the combination of these advanced therapies in multi-modal treatment strategies is increasingly common, aiming to enhance efficacy and reduce the likelihood of cancer recurrence.

The growth in the blood cancer therapeutics market is driven by several factors, including the increasing incidence of blood cancers globally, aging populations, and rising healthcare investments. Technological advancements in drug development and cancer genomics are also pivotal, as they lead to more effective and less toxic treatment options. Moreover, the expansion of clinical trials testing new drug combinations and sequences is accelerating the pace of innovation in this field. Public and private sector funding for cancer research plays a critical role, alongside advocacy and patient education efforts that raise awareness and access to the latest treatments. The market's expansion is further supported by regulatory agencies that are streamlining the approval processes for breakthrough therapies, thereby hastening their availability to patients.

Select Competitors (Total 42 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • Arcellx
  • BeiGene
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics, Inc.
  • Kite Pharma, Inc.
  • Kura Oncology
  • Novartis International AG
  • Oncolyze Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • TScan Therapeutics;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Blood Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Emerging Therapies and Breakthroughs in Blood Cancer Treatment
    • Personalized Medicine and Genetic Testing's Role in Therapy Selection
    • Increasing Global Prevalence of Blood Cancers Driving Research and Development
    • Role of Stem Cell Transplantation in Treatment Protocols
    • Advances in Immunotherapy and Its Market Impact
    • Regulatory Frameworks Facilitating Faster Drug Approvals
    • Patient Advocacy and Access to Experimental Treatments
    • Partnerships between Biotech Firms and Pharmaceutical Giants
    • Impact of Patent Expiries on Generic and Biosimilar Entry
    • Technological Advancements in Drug Delivery Systems
    • Epidemiological Shifts and Their Implications on Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Blood Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Blood Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Blood Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chronic Myeloid Leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chronic Myeloid Leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chronic Myeloid Leukemia (CML) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Acute Lymphocytic Leukemia (ALL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Acute Lymphocytic Leukemia (ALL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Acute Lymphocytic Leukemia (ALL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chronic Lymphocytic Leukemia (CLL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chronic Lymphocytic Leukemia (CLL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chronic Lymphocytic Leukemia (CLL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Acute Myeloid Leukemia (AML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Acute Myeloid Leukemia (AML) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Leukemia Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Leukemia Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Leukemia Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cancer Research Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cancer Research Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cancer Research Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cancer Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cancer Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Cancer Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Surgical Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Surgical Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Surgical Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • JAPAN
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • CHINA
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • EUROPE
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Blood Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Blood Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • FRANCE
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • GERMANY
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Blood Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Blood Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • INDIA
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 125: India Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 128: India Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: India 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Blood Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Blood Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Blood Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Blood Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030
  • AFRICA
    • Blood Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Blood Cancer Therapeutics by Leukemia Type - Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Blood Cancer Therapeutics by Leukemia Type - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML) and Other Leukemia Types for the Years 2014, 2024 & 2030
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Blood Cancer Therapeutics by End-Use - Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Blood Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Cancer Research Centers End-Use, Cancer Hospitals End-Use, Surgical Centers End-Use and Clinics End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION